TScan Therapeutics, Inc.

NASDAQ:TCRX

Biotechnology

Healthcare
$0.82 +2.23%

+$0.02 today

Market cap
$50.37M
Beta
1.03
P/E (TTM)
-1.0
EPS (TTM)
-$0.96
52W Low $0.85High $2.57

Volume 0.00M

Average 0.81M

TCRX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

TScan Therapeutics, Inc.NASDAQ: TCRX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $21.9M fell 26.5% year over year, behind the -5.4% change in trailing-twelve-month research & development. Sequentially, it rose 9.3% from the prior quarter. Over 3 fiscal years it compounded at +24.0% a year.

Context

  • Research & development amounted to 1105.6% of revenue in FY2025, down 2706.6 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -26.5% toward the trailing-twelve-month pace of -5.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$21.9M+9.3% QoQ
Last fiscal yearDec 2025
$114.15M+6.3% YoY
LTMMar 2026
$106.27M-5.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.5%——
1 year+6.3%——
3-year CAGR+24.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
114.15M USD
Year-over-year change
+6.3%
4-year CAGR
+26.2%

Research & Development vs competitors

How TCRX compares with its peers on the latest reported figures

  • TCRX's LTM Mar 2026 research & development of $106.27M is the 2nd highest of the 10 companies compared; the peer median is $59.66M.
  • Its year-over-year change of -5.4% is the 6th highest of 10, against a peer median of -4.5%.
  • Research & development amounts to 1163.2% of revenue for TCRX, versus a peer median of 78.3%.
TCRX Competitors Peer median
Research & Development for TCRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$200.25M +133.0%+35.5%78.3%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$106.27M -5.4%+24.0%1163.2%
ACETAdicet Bio, Inc.LTM Mar 2026$93.8M -4.5%+11.6%—
IMUXImmunic, Inc.LTM Mar 2026$86.08M +3.9%+4.8%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$67.7M +8.5%+10.6%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M -11.8%+35.8%—
XBITXBiotech Inc.LTM Mar 2026$40.98M +3.6%+14.5%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$23.02M -48.6%-81.3%—
FBIOFortress Biotech, Inc.LTM Mar 2026$8.51M -76.4%-55.5%12.9%
NTRBNutriband Inc.LTM Apr 2026$1.45M -48.6%+24.4%80.7%
Peer median (excluding TCRX) $59.66M-4.5%+11.6%78.3%

Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.14M13.54M21.05M2.82M10.33M
Cost of Revenue00002.87M
Gross Profit10.14M13.54M21.05M2.82M7.46M
Gross Margin100.0%100.0%100.0%100.0%72.2%
Research & Development44.95M59.82M88.15M107.35M114.15M
Selling, General & Admin13.83M20.35M25.49M29.56M31.99M
Operating Expenses58.78M80.17M114.51M137.64M143.27M
Depreciation & Amortization3.33M5.14M5.36M4.11M2.87M
EBITDA(45.3M)(59.91M)(80.1M)(119.74M)(124.13M)
EBITDA Margin-446.7%-442.6%-380.5%-4252.1%-1202.2%
Operating Income(48.64M)(66.64M)(93.46M)(134.82M)(135.81M)
Operating Margin-479.6%-492.3%-444.0%-4787.7%-1315.4%
Interest Income16K1.59M8M12.07M8.82M
Interest Expense01.18M3.76M3.65M2.77M
Other Income / Expenses16K415K4.24M7.32M6.05M
Income Before Tax(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Pre-Tax Margin-479.5%-489.3%-423.9%-4527.7%-1256.8%
Income Tax Expense00000
Net Income(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Net Margin-479.5%-489.3%-423.9%-4527.7%-1256.8%
EPS (Basic)(2.03)(2.74)(1.36)(1.14)(1.00)
EPS (Diluted)(2.03)(2.74)(1.36)(1.14)(1.00)
Weighted Avg Shares23.91M24.05M65.6M111.99M129.86M
Weighted Avg Shares (Diluted)23.91M24.05M65.6M111.99M129.86M

TScan Therapeutics, Inc.

NASDAQ:TCRX

Intrinsic Alpha fair value

Locked

Current Price

$0.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.